	US 12,226,453 B2
	Eosinophils alleviate lung allograft rejection through their modulation of CD8+ t cells
Alexander Sasha Krupnick, Charlottesville, VA (US); Yizhan Guo, Charlottesville, VA (US); and Oscar Okwudiri Onyema, Charlottesville, VA (US)
Assigned to University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed by University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed on Feb. 28, 2020, as Appl. No. 16/804,882.
Claims priority of provisional application 62/811,580, filed on Feb. 28, 2019.
Prior Publication US 2020/0276269 A1, Sep. 3, 2020
Int. Cl. A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61P 37/06 (2006.01)

CPC A61K 38/195 (2013.01) [A61K 38/2033 (2013.01); A61P 37/06 (2018.01)]

15 Claims

1. A method for enhancing immunosuppression in the lung of a subject, the method comprising administering to the subject a composition comprising at least one eosinophil recruiting agent, wherein the administering is in an amount and via a route of administration sufficient to induce recruitment of eosinophils to the lung of the subject to thereby enhance immunosuppression in the lung of the subject, and further wherein the lung is a transplanted lung in the subject, the subject is an otherwise non-immunosuppressed subject, and the immunosuppression is sufficient to reduce rejection of the transplanted lung in the subject.